Daniele Mauro

Real-world effectiveness and drug retention rate of risankizumab in patients with psoriatic arthritis: data from the multicentre GIRRCS cohort

Introduction Psoriatic arthritis (PsA) is a chronic heterogenous inflammatory disease characterized by a multidomain burden. Risankizumab, a selective inhibitor of the IL-23 p19 subunit, has shown efficacy in randomized trials; however, real-world data in PsA remain limited. We e...

Difficult-to-treat systemic lupus erythematosus: from refractory disease to a multidimensional clinical trajectory

Difficult-to-treat (D2T) systemic lupus erythematosus (SLE) is increasingly recognised in clinical practice but is still conceptually underdeveloped. In contrast to rheumatoid arthritis and psoriatic arthritis, for which formal D2T frameworks have been proposed, SLE still lacks a...